Evidence map›Paper›PMID 35777990›Full record

ArticleHuman immunology

Genetic variants in the NF-κB signaling pathway (NFKB1, NFKBIA, NFKBIZ) and risk of critical outcome among COVID-19 patients.

Daniel G Camblor, Daniel Miranda, Guillermo M Albaiceta, Laura Amado-Rodríguez, Elías Cuesta-Llavona, Daniel Vázquez-Coto, Julia Gómez de Oña, Claudia García-Lago, Juan Gómez, Eliecer Coto

Open access · greenAbstract read
In one paragraph

Article in Human immunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Daniel G CamblorGenética Molecular, Hospital Universitario Central Asturias, Oviedo, Spain.
Daniel MirandaGenética Molecular, Hospital Universitario Central Asturias, Oviedo, Spain.
Guillermo M AlbaicetaUnidad de Cuidados Intensivos Cardiológicos, Hospital Universitario Central Asturias, Oviedo, Spain; Instituto de Investigación Sanitaria del Principado de Asturias, ISPA, Oviedo, Spain; Universidad de Oviedo, Oviedo, Spain; CIBER-Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain; Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain.
Laura Amado-RodríguezUnidad de Cuidados Intensivos Cardiológicos, Hospital Universitario Central Asturias, Oviedo, Spain; Instituto de Investigación Sanitaria del Principado de Asturias, ISPA, Oviedo, Spain; Universidad de Oviedo, Oviedo, Spain; CIBER-Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain; Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain.
Elías Cuesta-LlavonaGenética Molecular, Hospital Universitario Central Asturias, Oviedo, Spain; Instituto de Investigación Sanitaria del Principado de Asturias, ISPA, Oviedo, Spain.
Daniel Vázquez-CotoGenética Molecular, Hospital Universitario Central Asturias, Oviedo, Spain.
Julia Gómez de OñaServicio de Medicina Intensiva, Hospital de Poniente, El Ejido, Spain.
Claudia García-LagoGenética Molecular, Hospital Universitario Central Asturias, Oviedo, Spain; Instituto de Investigación Sanitaria del Principado de Asturias, ISPA, Oviedo, Spain.
Juan GómezGenética Molecular, Hospital Universitario Central Asturias, Oviedo, Spain; Instituto de Investigación Sanitaria del Principado de Asturias, ISPA, Oviedo, Spain.
Eliecer CotoGenética Molecular, Hospital Universitario Central Asturias, Oviedo, Spain; Instituto de Investigación Sanitaria del Principado de Asturias, ISPA, Oviedo, Spain; Universidad de Oviedo, Oviedo, Spain. Electronic address: eliecer.coto@sespa.es.
Hospital Universitario Central de Asturias · ESInstituto de Investigación Sanitaria del Principado de Asturias · ESInstituto de Salud Carlos III · ESHospital de Poniente · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The NF-κB signaling pathway is a key regulator of inflammation in the response to SARS-CoV-2 infection. This pathway has been implicated in the hyperinflammatory state that characterizes the severe forms of COVID-19. The genetic variation of the NF-κB components might thus explain the predisposition to critical outcomes of this viral disease. We aimed to study the role of the common NFKB1 rs28362491, NFKBIA rs696 and NFKBIZ rs3217713 variants in the risk of developing severe COVID-19 with ICU admission. A total of 470 Spanish patients requiring respiratory support in the ICU were studied (99 deceased and 371 survivors). Compared to healthy population controls (N = 300), the NFKBIA rs696 GG genotype was increased in the patients (p = 0.045; OR = 1.37). The NFKBIZ rs3217713 insertion homozygosis was associated with a significant risk of death (p = 0.02; OR = 1.76) and was also related to increased D-dimer values (p = 0.0078, OR = 1.96). This gene has been implicated in sepsis in mice and rats. Moreover, we found a trend toward lower expression of the NFKBIZ transcript in total blood from II patients. In conclusion, variants in the NF-κB genes might be associated with the risk of developing severe COVID-19, with a significant effect of the NFKBIZ gene on mortality. Our results were based on a limited number of patients and require validation in larger cohorts from other populations.

Indexed as

COVID-19NF-kappa BAdaptor Proteins, Signal TransducingGenetic Association StudiesGenetic Predisposition to DiseaseHumansNF-KappaB Inhibitor alphaNF-kappa B p50 SubunitPolymorphism, Single NucleotideSARS-CoV-2Signal TransductionAdaptor Proteins, Signal TransducingNF-kappa BNF-KappaB Inhibitor alphaNF-kappa B p50 SubunitNFKB1 protein, humanNFKBIA protein, humanNFKBIZ protein, humanCOVID-19Gene polymorphismsGenetic associationNFKBIZNF-κB signaling pathway

Identifiers

PMID35777990
PMCPMC9212649
OpenAlexW4283218004

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.